

Emerging Infections Program— State Health Department Perspective

James L. Hadler, Richard N. Danila, Paul R. Cieslak, James I. Meek, William Schaffner,
Kirk E. Smith, Matthew L. Carter, Lee H. Harrison, Duc J. Vugia, Ruth Lynfield

The Emerging Infections Program (EIP) is a collaboration between the Centers for Disease Control and Prevention and 10 state health departments working with academic partners to conduct active population-based surveillance and special studies for several emerging infectious disease issues determined to need special attention. The Centers for Disease Control and Prevention funds the 10 EIP sites through cooperative agreements. Our objective was to highlight 1) what being an EIP site has meant for participating health departments and associated academic centers, including accomplishments and challenges, and 2) the synergy between the state and federal levels that has resulted from the collaborative relationship. Sharing these experiences should provide constructive insight to other public health programs and other countries contemplating a collaborative federal–local approach to collective public health challenges.

In 1994, the Centers for Disease Control and Prevention (CDC) created the domestic Emerging Infections Program (EIP) as part of the response to the 1992 Institute of Medicine report recommending “the development and implementation of strategies that would strengthen state and federal efforts in U.S. surveillance” (1,2). The EIP was established as a collaborative population-based surveillance program involving CDC, selected state health departments, and their chosen academic institution partners. The major objective of the EIP was to conduct active population-based surveillance for a range of domestic emerging infectious diseases for which either no surveillance was occurring or

state-level surveillance was occurring but “gold standard,” consistently high-quality surveillance was needed. The selected state health departments needed to engage clinical laboratories and infection control professionals throughout their jurisdictions. The relationship between CDC and the state health departments chosen to foster the EIP objectives has been a collaborative one, not purely a contractual relationship. Using a cooperative agreement funding mechanism, the federal, state, and academic collaborators have had shared responsibilities for setting priorities, planning and executing activities, and synthesizing and communicating results (3).

The infrastructure and expanded capacity that has resulted in terms of resources and collaborative relationships with CDC, between sites, and within each participating state have greatly enriched public health practice at each site and provided multiple state-based “laboratories” to pilot a variety of surveillance initiatives with possible national public health implications. The results have been remarkable: data to drive local and national public health initiatives have been gathered; state laboratory capacity to support surveillance has been updated and expanded, providing a model for expansion in other states; health threats from emerging infectious diseases have been identified and brought to national attention, and their epidemiology has been described; new methods to conduct surveillance have been piloted and adopted; staff in academic centers have become involved in public sector public health practice and research and expanded on them; and training and practice opportunities for public health students—the future epidemiology workforce—have multiplied.

In this article, our objectives are to describe 1) highlights of what being an EIP site has meant for participating health departments and associated academic centers, including accomplishments and challenges, and 2) the synergy between the state and federal levels that has resulted from the collaborative relationship. We hope that sharing these experiences will provide constructive insights to other public health program areas and other countries that are contemplating a collaborative national–local approach to collective public health challenges.

Author affiliations: Yale School of Public Health, New Haven, Connecticut, USA (J.L. Hadler, J.I. Meek); Minnesota Department of Health, St. Paul, Minnesota, USA (R.N. Danila, K.E. Smith, R. Lynfield); Oregon Health Authority, Portland, Oregon, USA (P.R. Cieslak); Vanderbilt University School of Medicine, Nashville, Tennessee, USA (W. Schaffner); Connecticut Department of Public Health, Hartford, Connecticut, USA (M.L. Carter); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (L.H. Harrison); California Department of Public Health, Richmond, California, USA (D.J. Vugia)

DOI: <http://dx.doi.org/10.3201/eid2109.150428>

Health Department Infrastructure and Surveillance Enhancements

Several critical state-level, surveillance-related infrastructural enhancements have resulted from being an EIP site. First, federal EIP funding has been substantial. In 2014, EIP sites received an average of \$3.6 million for personnel (including indirect costs), laboratory support, and supplies for all EIP projects in which they participated. This funding paid for a range of staff members, from 22 full-time equivalent (FTE) persons (spread over 27 positions) in the site with the smallest amount of personnel support to 58 FTEs (spread over 80 positions) in the site with the highest level of personnel support. The FTEs included staff in collaborating academic centers but excluded students in training positions.

Having additional epidemiology staff made it possible to conduct gold-standard surveillance for all diseases of EIP interest, with routine auditing of laboratories becoming an accepted feature of laboratory surveillance, thereby ensuring as close to 100% reporting from laboratories as possible. The experience and contacts from these efforts have made it possible for those running programs for non-EIP diseases (e.g., HIV, tuberculosis, sexually transmitted infections) to incorporate audits into their surveillance activities.

The additional resources, also made possible expansion of laboratory capacity to support surveillance. Additional staff enabled processing and storage of specimens of organisms from persons with invasive pneumococcal disease, group A *Streptococcus* (GAS) disease, and bacterial foodborne illness to enable typing and antimicrobial susceptibility testing, critical to the expanded surveillance role EIP sites have served for these infections. Updated laboratory capacity to perform pulsed-field gel electrophoresis enabled the EIPs to be in the forefront of identifying and investigating foodborne pathogen clusters and methicillin-resistant *Staphylococcus aureus* (MRSA) strains (4–7).

Second, incorporating laboratories, hospital infection prevention and control staff, and infectious disease physicians into the EIP sites by actively seeking their support and developing ways to share the information gathered from active surveillance has resulted in truly collaborative networks in each EIP site. Interest is such that in many sites EIP updates are a routine feature of grand rounds in some hospitals. Such interactions have resulted in more efficient and effective networks for communication and data dissemination, more efficient surveillance, and a sense of partnership among many of those involved (e.g., public health professionals, infectious disease clinicians, infection control practitioners, laboratorians) in contributing toward emerging infections work. These networks were used effectively during 2001–2003, before bioterrorism-related preparedness funding became available to support extensive communication systems in all states.

Third, in 2010, the EIPs began to conduct surveillance for health care–associated infections. Addition of capacity in this area has enabled EIP sites to move beyond encouraging hospitals to enroll in the National Healthcare Safety Network and produce annual reports of infection rates by hospital. EIP sites have established systems for ascertaining the number of central line–associated bloodstream infections within their entire catchment populations. Associated validation studies have identified limitations of definitions and enabled more complete case ascertainment. Methods have been established to enable estimation of the total number of nosocomial infections among hospitalized patients, setting the stage for repeated estimation to monitor trends over time (8). Interventions have been developed and studied for their effectiveness in some sites through communitywide collaboration.

Added Value of Academic Center Collaboration

Collaborations with academic health centers have enabled much greater flexibility in the types of surveillance and special studies that the EIPs and, correspondingly, the respective state health departments can undertake. These collaborations not only provide ready access to students looking to participate in research and public health practice projects but also provide easier access for hiring staff for specific short-term projects, making special risk factor studies easier to conduct. In addition, academic center–based staff can conduct intensive surveillance in smaller catchment areas, and interested faculty can collaborate in and enhance population-based surveillance research projects, including tying them into their clinical networks and efforts to seek funding. In Connecticut, for example, faculty from the Yale School of Medicine have taken advantage of, become involved in, and enhanced EIP surveillance for ehrlichiosis, neonatal sepsis, group A GAS disease, chronic liver disease, and precancerous cervical lesions caused by human papillomavirus (HPV) infection; they also have contributed to design and analysis of studies of the effectiveness of pneumococcal, rotavirus, and HPV vaccines. Infectious disease faculty and fellows at the Oregon Health and Science University have contributed to Oregon’s studies of *Clostridium difficile* diarrhea, emerging *Cryptococcus gattii* infections, nontuberculous mycobacterial infections, and surveillance and control of carbapenem-resistant *Enterobacteriaceae*. In Minnesota, collaborations with investigators at the University of Minnesota have enabled studies such as the assessment of variant influenza, matching of antimicrobial-resistant bacteria causing infections in animals with those causing infections in humans, and MRSA infections. In Tennessee, fellows and faculty from the Vanderbilt University School of Medicine have used local EIP data in studies of racial, geographic, and socioeconomic differences in the

distribution of pneumococcal serotypes causing invasive disease, group A GAS intracranial infections, invasive pneumococcal infections in patients with sickle cell disease, neonatal early-onset group B *Streptococcus* (GBS) disease, and hospitalizations for influenza. The training relationship established between the Tennessee Department of Health and Vanderbilt University led directly to the prompt recognition and investigation of a recent large, multistate outbreak of fungal meningitis caused by a contaminated injectable steroid product. In Maryland, faculty from Johns Hopkins University designed and led a multisite study using EIP data on risk factors for invasive meningococcal disease among high school students.

Local Use of Data

Being an EIP site has meant conducting surveillance and obtaining local data for diseases for which the site was not previously conducting surveillance, implementing and evaluating prevention activities that could be or were being used without evaluation by other states, and using the data to reinforce existing or establishing new local disease control guidance. Diseases with new surveillance data for local use have included neonatal GBS and MRSA infections, invasive GAS disease and pneumococcal disease, non-O157 Shiga toxin-producing *Escherichia coli* (STEC), hospitalizations for influenza, *C. difficile* diarrhea (community- and health care-associated), and precancerous lesions caused by HPV infection. Diseases with data that have enabled local reinforcement and enhancement of prevention efforts include neonatal GBS, meningococcal disease, pneumococcal disease, influenza, salmonellosis, and HPV infection. As a result of having and using these data at a local level, EIP sites have become a resource to other states about how such data can be used.

Site Contributions to the National EIP— Innovation and Synergy

The state-based EIP sites have contributed to the larger EIP in more ways than conducting the agreed-upon surveillance projects and special studies that have provided national-level data leading to new understanding and prevention initiatives on many fronts (3). In particular, these sites have been a source of ideas to be considered for new priority EIP projects, multiple and often independent “laboratories” for working out surveillance methods to meet changing needs, an attraction for local academic center staff to become involved and generate spin-off studies, and sources for training of future public health practitioners.

Innovation

The EIP has a Steering Committee comprising representation from CDC, participating state health departments, and their academic partners from all sites that meets at least

annually to discuss administrative matters, progress, and future scientific direction. Although CDC staff usually lead the discussion, goals and priorities are determined collaboratively. Projects originally proposed by EIP sites that have shaped EIP priorities include surveillance for community-associated MRSA (1996 Steering Committee meeting), surveillance for community-associated *C. difficile* infections (2006 FoodNet Steering Committee meeting), and routine analysis of data using area-based socioeconomic measures (2012 Steering Committee meeting). These ideas cut across internal CDC boundaries at the time they were proposed. MRSA and *C. difficile* infections had been largely considered nosocomial problems, housed in CDC’s Division of Healthcare Quality Promotion. Initially, finding the right group at CDC to take an interest in the community perspective proved challenging. Measurement and ongoing monitoring of health conditions and risk factors incorporating measures of socioeconomic status other than race/ethnicity was neither centralized nor a routine concern for most CDC infectious disease programs. As a result, the Steering Committee established a Health Equity Working Group to develop standards and set the agenda for incorporating measures of socioeconomic status into routine EIP surveillance (9).

EIP sites also have piloted methods testing the feasibility of conducting population-based surveillance for new conditions and responding to changing laboratory technology. EIP sites piloted various forms of surveillance for community-associated MRSA for several years before settling on a common method (6,7,10,11). Collectively, a subset of sites piloted a standardized surveillance method for both community- and hospital-onset *C. difficile* infections, a successful endeavor that resulted in its becoming a core EIP surveillance project (12,13). Similarly, a subset of EIP sites piloted a standard method for surveillance for precancerous lesions for cervical cancer, demonstrating that the method was feasible. Surveillance for HPV cervical cancer precursors is now a core project for 5 EIP sites (14) and is contributing substantially in the assessment of the effectiveness of the vaccine at a population level. When some laboratories stopped performing cultures for *E. coli* O157 and switched to testing for Shiga toxin, the ability to detect outbreaks and monitor trends in *E. coli* O157 was threatened. A pilot project at an EIP site demonstrated the feasibility of turning this crisis into an opportunity to conduct surveillance for both non-O157 and O157 STEC by having the state laboratory culture all Shiga toxin-positive broths into which feces had been inoculated (15). Subsequently, surveillance for non-O157 STEC became part of core FoodNet surveillance, and these infections are proving to be even more common than infection by the prototypical *E. coli* O157 strain. Finally, the periodic EIP-sponsored FoodNet Population Surveys have measured frequencies of consumption of a variety

of foods, including selected high-risk foods (e.g., alfalfa sprouts, unpasteurized milk). When such data were used in EIP sites as background rates in binomial probability calculations, they enabled rapid identification of food vehicles in outbreaks of salmonellosis, campylobacteriosis, and *E. coli* O157 infection (16–18). This method, coupled with confirmatory evidence from food tracebacks, case–control studies, or food testing, is now routinely used in many jurisdictions around the country (19–21).

Synergy

Collaborations with academic centers also have provided fertile ground for academic researchers to take advantage of the special surveillance projects being conducted in their midst to conduct spin-off projects, sometimes with funding from non-CDC sources. For example, in Connecticut, Yale University researchers have taken advantage of surveillance for ehrlichiosis, GAS, and HPV to conduct special studies beyond those commissioned through the EIP (22–26). Oregon’s high rates of disease caused by a clone of serogroup B *Neisseria meningitidis* led to a case–control study demonstrating a strong association with exposure to second-hand tobacco smoke (27) and to laboratory studies demonstrating the ability of *N. meningitidis* to alter its capsular polysaccharide (28). In Minnesota, academic partners have undertaken special studies of *S. aureus* (29) and GBS (30). In New York (Rochester) and Tennessee, the extent to which EIP surveillance for laboratory-confirmed influenza underestimated influenza-related hospitalizations in children was identified through collaboration and comparison with a research study with a different design than the EIP influenza surveillance (31).

Site-Specific Analyses

EIP sites own their site-specific data and can conduct and publish analyses of these data independently of direct CDC involvement. This ownership has greatly expanded the dissemination of EIP surveillance findings (2 sites alone have published 151 local analyses of data in peer-reviewed publications [online Technical Appendix, <http://wwwnc.cdc.gov/EID/article/21/9/15-0428-Techapp1.pdf>]). In addition, any site wanting to analyze all-site data can make a formal proposal to do so to the Steering Committee which if approved, gives it access to the de-identified all-site dataset (see online Technical Appendix for list of multisite publications led by 2 EIP sites). Overall, this flexibility has resulted not only in expanded dissemination of findings but also in expanded analytic creativity and data analysis capacity, and use of data for local and national purposes.

Training

In another article in this issue, Vugia et al. have summarized the contribution of EIP sites to training of the current

and future public health workforce (32). Although some training generated by EIP projects has occurred during the course of the CDC-based Epidemic Intelligence Service program and other CDC-based staff have gotten experience with data analysis, most training has occurred at the EIP sites as a result of the partnership in each site with an academic center. In 1 site alone, >190 students received training experiences during 1995–2014 (32). Of these, 75 students used their experience to fulfill thesis requirements, and 29 published an article in a peer-reviewed journal.

Challenges

Although being an EIP site has provided multiple benefits for the state health department and academic center at each site, these benefits have come with some challenges. These challenges include data management; need for frequent human subjects committee reviews of special surveillance and nonsurveillance protocols, often by multiple institutions; and dedicated staff to manage complex budgets and contracts. The funding received by sites does not include the substantial in-kind resources necessary to conduct a large multicomponent program, which also must be integrated with existing public health programs.

EIP sites have found that conducting surveillance and research activities requires attention to the logistics of data acquisition, storage, and distribution. Increasing quantities of data have required development within EIP sites of expanded data storage and handling capacity and increased facility with data systems. Many sites have developed home-grown systems capable of gleaning data electronically, making the data available for epidemiologic analysis, while exporting required fields to CDC for multisite data aggregation. Such systems need built-in flexibility—for example, ready ability to add new conditions or variables of relevance to public health stemming from the sorts of emerging disease problems on which EIPs are called to address. Informatics expertise has proved essential.

In many sites, the EIP is the major source of protocols submitted to institutional review boards (IRBs). Whether a given EIP endeavor constitutes “research” meeting the federal definition (i.e., “designed to develop or contribute to generalizable knowledge” [33]) is not always clear because analysis of routinely collected surveillance data may provide knowledge that is, at least in some sense, generalizable. CDC routinely analyzes data generated by state public health agencies in the course of ascertaining and controlling reportable diseases to identify new risk factors and trends that may well be generalizable; not surprisingly, CDC and state health departments often have arrived at different determinations as to whether a given EIP activity constituted research. Moreover, some university collaborators consider any study in which its students are engaged to be research, requiring the protocol’s review by its IRB. The requirement

that all IRBs approve the final protocol, and the multiplicity of IRBs (including those of individual hospitals, reviewing and imposing their own requirements on each protocol) for a 10-site EIP study involving university collaboration, can consume considerable time and effort.

With time, activities and expectations for EIPs have expanded, a fact welcomed by most sites. However, funding for the administrative work required by such expansions, including budget, contracts, and IRB tracking, and for hiring experienced epidemiologists to lead new projects has not always kept pace. EIPs note that funding increasingly must be directed to specified projects, leaving them with little flexibility and reduced ability to move beyond collecting data to writing articles for publication or crafting new protocols. As a consequence, such activities are increasingly left to CDC, jeopardizing some of the synergy of the collaborative partnership.

Given the challenges we describe and the frequent necessary coordination of surveillance and epidemiologic activities between local hospitals, laboratories, health departments, and state and federal partners, the structural setup that most EIP sites worked out is one in which the program is located within the lead state health department with or without a co-location within the lead partner school of public health or medicine.

Summary

The collaborative nature of the EIP has resulted in enhanced surveillance and laboratory capacity and communication networks in the 10 state public health departments. In addition, it has enriched research and public health training at the partner academic centers and produced synergy with the involved CDC programs, broadening the creativity and data analytic and dissemination capacity of all involved entities.

Acknowledgments

We acknowledge the contributions of the members of the EIP Steering Committee, past and present, for their collaborative work to make the EIP more than the sum of its component parts.

The work on this manuscript was supported by CDC Cooperative Agreement 5U50-CK000195.

Dr. Hadler has worked with the EIP since its inception in 1995, first as the Connecticut State Epidemiologist and more recently based at the Yale School of Public Health, where he is Clinical Professor of Epidemiology. He was a member of the EIP Steering Committee during 1995–2008.

References

1. Institute of Medicine. Emerging infections: microbial threats to health in the United States. Washington, DC: National Academy Press; 1992 [cited 2015 Jun 25]. <http://iom.edu/Reports/1992/Emerging-Infections-Microbial-Threats-to-Health-in-the-United-States.aspx>
2. Pinner RW. Addressing the challenges of emerging infectious disease. *Am J Med Sci*. 1996;311:3–8. <http://dx.doi.org/10.1097/00000441-199601000-00002>
3. Pinner RW, Lynfield R, Hadler JL, Schaffner W, Farley MM, Frank ME, et al. Cultivation of an adaptive domestic network for surveillance and evaluation of emerging infections. *Emerg Infect Dis*. 2015;21:1499–1509.
4. Bender JB, Hedberg CW, Besser JM, Boxrud DJ, MacDonald KL, Osterholm MT. Surveillance for *Escherichia coli* O157:H7 infections in Minnesota by molecular subtyping. *N Engl J Med*. 1997;337:388–94. <http://dx.doi.org/10.1056/NEJM199708073370604>
5. Bender JB, Hedberg CW, Boxrud DJ, Besser JM, Wicklund JH, Smith KE, et al. Use of molecular subtyping in surveillance for *Salmonella enterica* serotype Typhimurium. *N Engl J Med*. 2001;344:189–95. <http://dx.doi.org/10.1056/NEJM200101183440305>
6. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA*. 2007;298:1763–71. <http://dx.doi.org/10.1001/jama.298.15.1763>
7. Hadler JL, Petit S, Mandour M, Cartter ML. Trends in invasive infection with methicillin-resistant *Staphylococcus aureus*, Connecticut, USA, 2001–2010. *Emerg Infect Dis*. 2012;18:917–24.
8. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care–associated infections. *N Engl J Med*. 2014;370:1198–208. <http://dx.doi.org/10.1056/NEJMoa1306801>
9. Hadler JL, Vugia DJ, Bennett NM, Moore MR. Emerging Infections Program efforts to address health equity. *Emerg Infect Dis*. 2015;21:1589–1594.
10. Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset *Staphylococcus aureus* infections with bacteremia in 4 metropolitan Connecticut areas, 1998. *J Infect Dis*. 2001;184:1029–34. <http://dx.doi.org/10.1086/323459>
11. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant *Staphylococcus aureus* disease in three communities. *N Engl J Med*. 2005;352:1436–44. <http://dx.doi.org/10.1056/NEJMoa043252>
12. Hirshon JM, Thompson AD, Limbago B, McDonald LC, Bonkosky M, Heimer R, et al. *Clostridium difficile* infection in outpatients, Maryland and Connecticut, USA, 2002–2007. *Emerg Infect Dis*. 2011;17:1946–9. <http://dx.doi.org/10.3201/eid1710.110069>
13. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated *Clostridium difficile* infection, 2009 through 2011. *JAMA Intern Med*. 2013;173:1359–67. <http://dx.doi.org/10.1001/jamainternmed.2013.7056>
14. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, et al. the HPV-IMPACT Working Group. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. *Cancer Causes Control*. 2012;23:281–8. <http://dx.doi.org/10.1007/s10552-011-9877-6>
15. Centers for Disease Control and Prevention. Laboratory-confirmed non-O157 Shiga toxin–producing *Escherichia coli*—Connecticut, 2000–2005. *MMWR Morb Mortal Wkly Rep*. 2007;56:29–31.
16. Centers for Disease Control and Prevention. Outbreak of *Salmonella* serotype Enteritidis infections associated with raw almonds—United States and Canada, 2003–2004. *MMWR Morb Mortal Wkly Rep*. 2004;53:484–7.
17. Public Health Division, Oregon Department of Health Services. An outbreak of hemorrhagic escherichiosis traced to spinach. *CD Summary* 2006;55:1–2 [cited 2015 Feb 27]. <https://public.health.oregon.gov/DiseasesConditions/CommunicableDisease/CDSummaryNewsletter/Documents/2006/ohd5523.pdf>

18. Lujan K, Cronquist A. Outbreak # 2009–43–001—*Campylobacter* outbreak associated with consumption of unpasteurized milk from a cow share operation, Montrose County 2009. State of Colorado report, November 6, 2009 [cited 2015 Feb 27]. <http://www.realrawmilkfacts.com/PDFs/Montrose-raw-dairy-report-Final.pdf>
19. Angelo KM, Chu A, Anand M, Nguyen TA, Bottichio L, Wise M, et al. Outbreak of *Salmonella* Newport infections linked to cucumbers—United States, 2014. *MMWR Morb Mortal Wkly Rep*. 2015;64:144–7.
20. Slayton RB, Turabelidze G, Bennett SD, Schwensohn CA, Yaffee AQ, Khan F, et al. Outbreak of Shiga toxin–producing *Escherichia coli* (STEC) O157:H7 associated with romaine lettuce consumption, 2011. *PLoS ONE*. 2013;8:e55300. <http://dx.doi.org/10.1371/journal.pone.0055300>
21. Centers for Disease Control and Prevention. Outbreak of *Salmonella* Heidelberg infections linked to a single poultry producer—13 states, 2012–2013. *MMWR Morb Mortal Wkly Rep*. 2013;62:553–6.
22. IJdo JW, Zhang Y, Hodzic E, Magnarelli LA, Wilson ML, Telford SR, et al. The early humoral response in human granulocytic ehrlichiosis. *J Infect Dis*. 1997;176:687–92. <http://dx.doi.org/10.1086/514091>
23. Bessen DE, Izzo MW, Fiorentino TR, Caringal RM, Hollingshead SK, Beall B. Genetic linkage of exotoxin alleles and emm gene markers for tissue tropism in group A streptococci. *J Infect Dis*. 1999;179:627–36. <http://dx.doi.org/10.1086/314631>
24. Niccolai LM, McBride V, Julian PR. Sources of information for assessing human papillomavirus vaccination history among young women. *Vaccine*. 2014;32:2945–7. <http://dx.doi.org/10.1016/j.vaccine.2014.03.059>
25. Niccolai LM, Mehta NR, Hadler JL. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. *Am J Prev Med*. 2011;41:428–33. <http://dx.doi.org/10.1016/j.amepre.2011.06.032>
26. Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, et al. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: associations with race, ethnicity and poverty. *Cancer*. 2013;119:3052–8. <http://dx.doi.org/10.1002/ncr.28038>
27. Fischer M, Hedberg K, Cardosi P, Plikaytis BD, Hoesly FC, Steingart KR, et al. Tobacco smoke as a risk factor for meningococcal disease. *Pediatr Infect Dis J*. 1997;16:979–83. <http://dx.doi.org/10.1097/00006454-199710000-00015>
28. Swartley JS, Marfin AA, Edupuganti S, Liu LJ, Cieslak P, Perkins B, et al. Capsule switching of *Neisseria meningitidis*. *Proc Natl Acad Sci U S A*. 1997;94:271–6. <http://dx.doi.org/10.1073/pnas.94.1.271>
29. DeVries AS, Leshner L, Schlievert PM, Rogers T, Villaume LG, Danila R, et al. Staphylococcal toxic shock syndrome 2000–2006: epidemiology, clinical features, and molecular characteristics. *PLoS ONE*. 2011;6:e22997. <http://dx.doi.org/10.1371/journal.pone.0022997>
30. Ferrieri P, Lynfield R, Creti R, Flores AE. Serotype IV and invasive group B *Streptococcus* disease in neonates, Minnesota, USA, 2000–2010. *Emerg Infect Dis*. 2013;19:551–8.
31. Grijalva CG, Weinberg GA, Bennett NM, Staat MA, Craig AS, Dupont WD, et al. Estimating the undetected burden of influenza hospitalizations in children. *Epidemiol Infect*. 2007;135:951–8. <http://dx.doi.org/10.1017/S095026880600762X>
32. Vugia DJ, Meek JI, Danila RN, Jones TF, Schaffner W, Baumbach J, et al. Training in infectious disease epidemiology through the Emerging Infections Program sites. *Emerg Infect Dis*. 2015;21:1516–1519.
33. Public Welfare. Protection of Human Subjects. 45 CFR §46 102(d). 2009.

Address for correspondence: James L. Hadler, Emerging Infections Program, Yale School of Public Health, 1 Church St, 7th Fl, New Haven, CT 06511, USA; email: hadler-epi@att.net

etymologia

Surveillance [sər-vāl'əns]

From the French *surveiller*, “to watch over,” public health surveillance has its roots in 14th-century Europe. In an early form of surveillance, in approximately 1348, the Venetian Republic appointed guardians of public health to detect and exclude ships that carried plague-infected passengers. In 1662, English demographer John Graunt analyzed the mortality rolls in London and described a system to warn of the onset and spread of plague. Until the 1950s, “surveillance” referred to monitoring a person exposed to a disease; the current concept of surveillance as monitoring disease occurrence in populations was promoted by Alexander Langmuir of the Communicable Diseases Center (now the Centers for Disease Control and Prevention).

Sources

1. Declich S, Carter AO. Public health surveillance: historical origins, methods and evaluation. *Bull World Health Organ*. 1994;72:285–304.
2. Dorland’s Illustrated Medical Dictionary. 32nd ed. Philadelphia: Elsevier Saunders; 2012.



Image courtesy Phillip Martin clip art, <http://architecture.phillipmartin.info/>

Address for correspondence: Ronnie Henry, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03, Atlanta, GA 30329-4027, USA; email: boq3@cdc.gov

DOI: <http://dx.doi.org/10.3201/eid2109.ET2109>

Emerging Infections Program—State Health Department Perspective

Technical Appendix

EIP Site-Specific Peer-Reviewed Publications, Connecticut and Minnesota, 1996–2014

Connecticut

1. Roberts CL, Morin CA, Addiss DG, Wahlquist SP, Mshar PA, Hadler JL. Factors influencing *Cryptosporidium* testing in Connecticut. J Clin Microbiol. 1996;34:2292–3. [PubMed](#)
2. Fiorentino TR, Beall B, Mshar P, Bessen DE. A genetic-based evaluation of the principal tissue reservoir for group A streptococci isolated from normally sterile sites. J Infect Dis. 1997;176:177–82. [PubMed](#) <http://dx.doi.org/10.1086/514020>
3. Morin CA, Roberts CL, Mshar PA, Addiss DG, Hadler JL. What do physicians know about cryptosporidiosis? A survey of Connecticut physicians. Arch Intern Med. 1997;157:1017–22. [PubMed](#) <http://dx.doi.org/10.1001/archinte.1997.00440300137012>
4. Centers for Disease Control and Prevention. Statewide surveillance for ehrlichiosis—Connecticut and New York, 1994–1997. MMWR Morb Mortal Wkly Rep. 1998;47:476–80. [PubMed](#)
5. Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting—Connecticut, Georgia, and Minnesota, 1997–1998 [Connecticut section]. MMWR Morb Mortal Wkly Rep. 1999;48:426–8. [PubMed](#)
6. Roome AJ, Hadler JL. Early-onset group B streptococcal disease—United States, 1998–1999 [Connecticut section]. MMWR Morb Mortal Wkly Rep. 2000;49:793–6.
7. IJdo JW, Meek JI, Cartter ML, Magnarelli LA, Wu C, Tenuta SW, et al. The emergence of another tickborne infection in the 12-town area around Lyme, Connecticut: human granulocytic ehrlichiosis. J Infect Dis. 2000;181:1388–93. [PubMed](#) <http://dx.doi.org/10.1086/315389>

8. Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers—Connecticut and Minnesota, 1998 [Connecticut section]. *MMWR Morb Mortal Wkly Rep.* 2000;49:228–32. [PubMed](#)
9. Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset *Staphylococcus aureus* infections with bacteremia in four metropolitan areas in Connecticut, 1998. *J Infect Dis.* 2001;184:1029–34. [PubMed](#) <http://dx.doi.org/10.1086/323459>
10. Kluger MD, Sofair AN, Heye CJ, Meek JI, Sodhi RK, Hadler JL. Retrospective validation of a surveillance system for unexplained illness and death: New Haven County, Connecticut. *Am J Public Health.* 2001;91:1214–9. [PubMed](#) <http://dx.doi.org/10.2105/AJPH.91.8.1214>
11. Chaput EK, Meek JI, Heimer R. Spatial analysis of human granulocytic ehrlichiosis near Lyme, Connecticut. *Emerg Infect Dis.* 2002;8:943–8. [PubMed](#) <http://dx.doi.org/10.3201/eid0809.020103>
12. Rabatsky-Ehr T, Dingman D, Marcus R, Howard R, Kinney A, Mshar P. Deer meat as the source for a sporadic case of *Escherichia coli* O157:H7 infection, Connecticut. *Emerg Infect Dis.* 2002;8:525–7. [PubMed](#) <http://dx.doi.org/10.3201/eid0805.010373>
13. Navarro VJ, St Louis T, Bell BP, Sofair AN. Chronic liver disease in the primary care practices of Waterbury, Connecticut. *Hepatology.* 2003;38:1062. [PubMed](#) <http://dx.doi.org/10.1002/hep.1840380439>
14. Navarro VJ, St Louis TE, Bell BP. Identification of patients with hepatitis C virus infection in New Haven County primary care practices. *J Clin Gastroenterol.* 2003;36:431–5. [PubMed](#) <http://dx.doi.org/10.1097/00004836-200305000-00015>
15. Trooskin SB, Hadler J, St Louis T, Navarro VJ. Geospatial analysis of hepatitis C in Connecticut: a novel application of a public health tool. *Public Health.* 2005;119:1042–7. [PubMed](#) <http://dx.doi.org/10.1016/j.puhe.2005.03.016>
16. Centers for Disease Control and Prevention. Laboratory-confirmed non-O157 Shiga toxin–producing *E. coli* surveillance—Connecticut, 2000–2005. *MMWR Morb Mortal Wkly Rep.* 2007;56:29–31. [PubMed](#)
17. Palumbo JP, Meek JI, Fazio DM, Turner SB, Hadler JL, Sofair AN. Unexplained deaths in Connecticut during 2002–2003: failure to consider Category A bioterrorism agents in differential diagnoses. *Disaster Med Public Health Prep.* 2008;2:87–94. [PubMed](#) <http://dx.doi.org/10.1097/DMP.0b013e318161315b>

18. Vázquez M, Muehlenbein C, Cartter M, Hayes EB, Ertel S, Shapiro ED. Effectiveness of personal protective measures to prevent Lyme disease. *Emerg Infect Dis*. 2008;14:210–6. [PubMed](#)
<http://dx.doi.org/10.3201/eid1402.070725>
19. Marcus R. New information about pediatric foodborne infections: the view from FoodNet. *Curr Opin Pediatr*. 2008;20:79–84. [PubMed](#) <http://dx.doi.org/10.1097/MOP.0b013e3282f43067>
20. Durante AJ, Meek JI, St Louis T, Navarro VJ, Sofair AN. Quantifying the burden of chronic viral hepatitis–related cirrhosis hospitalizations in New Haven County, Connecticut. *Conn Med*. 2008;72:393–7. [PubMed](#)
21. Durante AJ, St Louis T, Meek JI, Navarro VJ, Sofair AN. The mortality burden of chronic liver disease may be substantially underestimated in the United States. *Conn Med*. 2008;72:389–92. [PubMed](#)
22. Henrich TJ, Lauder N, Desai MM, Sofair AN. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. *J Community Health*. 2008;33:69–77. [PubMed](#)
<http://dx.doi.org/10.1007/s10900-007-9069-1>
23. Centers for Disease Control and Prevention. Surveillance for community-associated *C. difficile*—Connecticut, 2006. *MMWR Morb Mortal Wkly Rep*. 2008;57:340–3. [PubMed](#)
24. Wolfson JJ, Jandhyala DM, Gorczyca LA, Qadeer A, Thorpe CM, Manning SD, et al. Prevalence of the operon encoding subtilase cytotoxin in non-O157 STEC isolated from humans in the United States. *J Clin Microbiol*. 2009;47:3058–9. [PubMed](#) <http://dx.doi.org/10.1128/JCM.00706-09>
25. Sofair AN, Huie-White S, Stabach N, Fine N, Wright R. Use of fax-back surveillance to determine epidemiologic and clinical characteristics of patients diagnosed with hepatitis C in Waterbury, Connecticut. *Conn Med*. 2009;73:593–5. [PubMed](#)
26. Marcus R, Hurd S, Mank L, Mshar P, Phan Q, Jackson K, et al. Chicken salad as the source of a case of *Listeria monocytogenes* infection in Connecticut. *J Food Prot*. 2009;72:2602–6. [PubMed](#)
27. Connally NP, Durante AJ, Yousey-Hindes KM, Meek JI, Nelson RS, Heimer R. Peridomestic Lyme disease prevention: results of a population-based case–control study. *Am J Prev Med*. 2009;37:201–6. [PubMed](#) <http://dx.doi.org/10.1016/j.amepre.2009.04.026>
28. Backman LA, Melchreit R, Rodriguez R. Validation of the surveillance and reporting of central line–associated bloodstream infection data to a state health department. *Am J Infect Control*. 2010;38:832–8. [PubMed](#) <http://dx.doi.org/10.1016/j.ajic.2010.05.016>

29. Desai SN, Esposito DB, Shapiro ED, Dennehy PH, Vazquez M. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. *Vaccine*. 2010;28:7501–6. [PubMed http://dx.doi.org/10.1016/j.vaccine.2010.09.013](http://dx.doi.org/10.1016/j.vaccine.2010.09.013)
30. Niccolai LM, Mehta NL, Hadler JL. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. *Am J Prev Med*. 2011;41:428–33. [PubMed http://dx.doi.org/10.1016/j.amepre.2011.06.032](http://dx.doi.org/10.1016/j.amepre.2011.06.032)
31. Hadler JL, Clogher P, Phan Q, Hurd S, Mandour M, Bemis K, et al. Ten year trends and risk factors for non-O157 Shiga-toxin producing *E. coli* found through Shiga-toxin testing, Connecticut, 2000–2009. *Clin Infect Dis*. 2011;53:269–76. [PubMed http://dx.doi.org/10.1093/cid/cir377](http://dx.doi.org/10.1093/cid/cir377)
32. Soto K, Petit S, Hadler JL. Changing disparities in invasive pneumococcal disease by socioeconomic status and race in Connecticut, 1998–2008. *Public Health Rep*. 2011;126(Suppl 3):81–8. [PubMed http://dx.doi.org/10.1093/phr/khp013](http://dx.doi.org/10.1093/phr/khp013)
33. Yousey-Hindes KM, Hadler JL. Neighborhood socioeconomic status and influenza hospitalizations in children: New Haven County, Connecticut, 2003–2010. *Am J Public Health*. 2011;101:1785–9. [PubMed http://dx.doi.org/10.2105/AJPH.2011.300224](http://dx.doi.org/10.2105/AJPH.2011.300224)
34. Niccolai LM, Julian PJ, Bilinski A, Mehta NR, Meek JL, Zelterman D, et al. Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008–2009. *Am J Public Health*. 2013;103:156–63. [PubMed http://dx.doi.org/10.2105/AJPH.2011.300447](http://dx.doi.org/10.2105/AJPH.2011.300447)
35. Hadler JL, Petit S, Mandour M, Cartter ML. Trends in invasive infection with methicillin-resistant *Staphylococcus aureus*, Connecticut, USA, 2001–2010. *Emerg Infect Dis*. 2012;18:917–24. [PubMed http://dx.doi.org/10.3201/eid1806.120182](http://dx.doi.org/10.3201/eid1806.120182)
36. Mehta NR, Julian PJ, Meek JI, Sosa LE, Bilinski A, Hariri S, et al. Human papillomavirus vaccination history among women with precancerous cervical lesions: disparities and barriers. *Obstet Gynecol*. 2012;119:575–81. [PubMed http://dx.doi.org/10.1097/AOG.0b013e3182460d9f](http://dx.doi.org/10.1097/AOG.0b013e3182460d9f)
37. DeCew AE, Hadler JL, Moriarty-Daly A, Niccolai L. The prevalence of HPV associated disease in women under age 21: who will be missed under the new cervical cancer screening guidelines? *J Pediatr Adolesc Gynecol*. 2013;26:346–9. [PubMed http://dx.doi.org/10.1016/j.jpag.2013.06.013](http://dx.doi.org/10.1016/j.jpag.2013.06.013)
38. Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE. Declining rates of high-grade cervical lesions in young women in Connecticut, USA, 2008–2011. *Cancer Epidemiol Biomarkers Prev*. 2013;22:1446–50. [PubMed http://dx.doi.org/10.1158/1078-0432.CCR.12.2211](http://dx.doi.org/10.1158/1078-0432.CCR.12.2211)

39. Connally NP, Yousey-Hindes K, Meek J. Selection of neighborhood controls for a population-based Lyme disease case-control study by using a commercial marketing database. *Am J Epidemiol*. 2013;178:276–9. [PubMed](#) <http://dx.doi.org/10.1093/aje/kws464>
40. Nicolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, et al. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: associations with race, ethnicity and poverty. *Cancer*. 2013;119:3052–8. [PubMed](#) <http://dx.doi.org/10.1002/cncr.28038>
41. Bemis K, Marcus R, Hadler JL. Socioeconomic status and campylobacteriosis, Connecticut, USA, 1999–2009. *Emerg Infect Dis*. 2014;20:1240–2. [PubMed](#)
42. Hadler JL, Yousey-Hindes K, Kudish K, Sacco V, Cartter ML. Evaluation of the initial impact of a requirement for influenza vaccination of children attending licensed childcare or preschool programs—Connecticut 2013. *MMWR Morb Mortal Wkly Rep*. 2014;63:181–5. [PubMed](#)
43. Tam K, Yousey-Hindes K, Hadler JL. Influenza-related hospitalizations of adults associated with low census tract-level socioeconomic status and female sex in New Haven County, CT 2005–2011. *Influenza Other Respir Viruses*. 2014;8:274–81. <http://dx.doi.org/10.1111/irv.12231>
44. Nicolai LM, McBride V, Julian PR. Sources of information for assessing human papillomavirus vaccination history among young women. *Vaccine*. 2014;32:2945–7. [PubMed](#) <http://dx.doi.org/10.1016/j.vaccine.2014.03.059>
45. Waggaman C, Julian P, Nicolai LM. Interactive effects of individual and neighborhood race and ethnicity on rates of high-grade cervical lesions. *Cancer Epidemiol*. 2014;38:248–52. [PubMed](#) <http://dx.doi.org/10.1016/j.canep.2014.03.004>

Minnesota

1. Bender JB, Hedberg CW, Besser JM, Boxrud DJ, MacDonald KL, Osterholm MT. Surveillance for *Escherichia coli* O157:H7 infections in Minnesota by molecular subtyping. *N Engl J Med*. 1997;337:388–94. [PubMed](#) <http://dx.doi.org/10.1056/NEJM199708073370604>
2. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, et al. Quinolone-resistant *Campylobacter jejuni* infections in Minnesota, 1992–1998. *N Engl J Med*. 1999;340:1525–32. [PubMed](#) <http://dx.doi.org/10.1056/NEJM199905203402001>
3. Hedberg CW, Angulo FJ, White KE, Langkop CW, Schell WL, Stobierski MG, et al. Outbreaks of salmonellosis associated with eating uncooked tomatoes: implications for public health. *Epidemiol Infect*. 1999;122:385–93. [PubMed](#) <http://dx.doi.org/10.1017/S0950268899002393>

4. Bender JB, Smith KE, Hedberg C, Osterholm MT. Food-borne disease in the 21st century. What challenges await us? *Postgrad Med.* 1999;106:109–12, 15–6, 19.
5. Danila RN, Lexau C, Lynfield R, Moore KA, Osterholm MT. Addressing emerging infections. The partnership between public health and primary care physicians. *Postgrad Med.* 1999;106:90–2, 7–8, 103–5.
6. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine—United States, 1998–1999 [Minnesota section]. *MMWR Morb Mortal Wkly Rep.* 1999;48:577–81. [PubMed](#)
7. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant *Staphylococcus aureus*, Minnesota and North Dakota, 1997–1998 [Minnesota section]. *MMWR Morb Mortal Wkly Rep.* 1999;48:707–10. [PubMed](#)
8. Rainbow J, Lynfield R, Johnson JR, Danila RN. Minnesota surveillance for unexplained deaths and critical illnesses of possible infectious cause. *Minn Med.* 2000;83:51–3. [PubMed](#)
9. Deneen VC, Hunt JM, Paule CR, James RI, Johnson RG, Raymond MJ, et al. The impact of foodborne calicivirus disease: the Minnesota experience. *J Infect Dis.* 2000;181(Suppl 2):S281–3. [PubMed](#)
<http://dx.doi.org/10.1086/315583>
10. Centers for Disease Control and Prevention. Adoption of perinatal group B streptococcal disease prevention recommendations by prenatal-care providers—Connecticut and Minnesota, 1998 [Minnesota section]. *MMWR Morb Mortal Wkly Rep.* 2000;49:228–32. [PubMed](#)
11. Bender JB, Hedberg CW, Boxrud DJ, Besser JM, Wicklund JH, Smith KE, et al. Use of molecular subtyping in surveillance for *Salmonella enterica* serotype Typhimurium. *N Engl J Med.* 2001;344:189–95. [PubMed](#) <http://dx.doi.org/10.1056/NEJM200101183440305>
12. Ehresmann KR, Ramesh A, Como-Sabetti K, Peterson DC, Whitney CG, Moore KA. Factors associated with self-reported pneumococcal immunization among adults 65 years of age or older in the Minneapolis–St. Paul metropolitan area. *Prev Med.* 2001;32:409–15. [PubMed](#)
<http://dx.doi.org/10.1006/pmed.2001.0839>
13. Naimi T, Ringwald P, Besser R, Thompson S. Antimicrobial resistance. *Emerg Infect Dis.* 2001;7(Suppl):548. [PubMed](#) <http://dx.doi.org/10.3201/eid0707.017727>
14. Hedberg CW, Smith KE, Besser JM, Boxrud DJ, Hennessy TW, Bender JB, et al. Limitations of pulsed-field gel electrophoresis for the routine surveillance of *Campylobacter* infections. *J Infect Dis.* 2001;184:242–4. [PubMed](#) <http://dx.doi.org/10.1086/322005>

15. Centers for Disease Control and Prevention. Update: unexplained deaths following knee surgery—Minnesota, November 2001. MMWR Morb Mortal Wkly Rep. 2001;50:1035–6. [PubMed](#)
16. Centers for Disease Control and Prevention. Unexplained deaths following knee surgery—Minnesota, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:1080. [PubMed](#)
17. Groom AV, Wolsey DH, Naimi TS, Smith K, Johnson S, Boxrud D, et al. Community-acquired methicillin-resistant *Staphylococcus aureus* in a rural American Indian community. JAMA. 2001;286:1201–5. [PubMed](#) <http://dx.doi.org/10.1001/jama.286.10.1201>
18. Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson SK, et al. Epidemiology and clonality of community-acquired methicillin-resistant *Staphylococcus aureus* in Minnesota, 1996–1998. Clin Infect Dis. 2001;33:990–6. [PubMed](#) <http://dx.doi.org/10.1086/322693>
19. Naimi TS, Anderson D, O’Boyle C, Boxrud DJ, Johnson SK, Tenover FC, et al. Vancomycin-intermediate *Staphylococcus aureus* with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis. 2003;36:1609–12. [PubMed](#) <http://dx.doi.org/10.1086/375228>
20. Johnson JR, Clabots C, Azar M, Boxrud DJ, Besser JM, Thurn JR. Molecular analysis of a hospital cafeteria-associated salmonellosis outbreak using modified repetitive element PCR fingerprinting. J Clin Microbiol. 2001;39:3452–60. [PubMed](#) <http://dx.doi.org/10.1128/JCM.39.10.3452-3460.2001>
21. Bartkus JM, Juni BA, Ehresmann K, Miller CA, Sanden GN, Cassiday PK, et al. Identification of a mutation associated with erythromycin resistance in *Bordetella pertussis*: implications for surveillance of antimicrobial resistance. J Clin Microbiol. 2003;41:1167–72. [PubMed](#) <http://dx.doi.org/10.1128/JCM.41.3.1167-1172.2003>
22. Naimi TS, Wicklund JH, Olsen SJ, Krause G, Wells JG, Bartkus JM, et al. Concurrent outbreaks of *Shigella sonnei* and enterotoxigenic *Escherichia coli* infections associated with parsley: implications for surveillance and control of foodborne illness. J Food Prot. 2003;66:535–41. [PubMed](#)
23. Naimi TS, Anderson D, O’Boyle C, Boxrud DJ, Johnson SK, Tenover FC, et al. Vancomycin-intermediate *Staphylococcus aureus* with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis. 2003;36:1609–12. [PubMed](#) <http://dx.doi.org/10.1086/375228>

24. Ogunmodede F, Virnig BA, Danila R, Lynfield R. Prevention of perinatal group B streptococcal disease in Minnesota: results from a retrospective cohort study and new prevention guidelines. *Minn Med*. 2003;86:40–5. [PubMed](#)
25. Johnson JR, Murray AC, Gajewski A, Sullivan M, Snippes P, Kuskowski MA, et al. Isolation and molecular characterization of nalidixic acid–resistant extraintestinal pathogenic *Escherichia coli* from retail chicken products. *Antimicrob Agents Chemother*. 2003;47:2161–8. [PubMed](#)
<http://dx.doi.org/10.1128/AAC.47.7.2161-2168.2003>
26. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and health care–associated methicillin-resistant *Staphylococcus aureus* infection. *JAMA*. 2003;290:2976–84. [PubMed](#) <http://dx.doi.org/10.1001/jama.290.22.2976>
27. Bender JB, Shulman SA. Reports of zoonotic disease outbreaks associated with animal exhibits and availability of recommendations for preventing zoonotic disease transmission from animals to people in such settings. *J Am Vet Med Assoc*. 2004;224:1105–9. [PubMed](#)
<http://dx.doi.org/10.2460/javma.2004.224.1105>
28. Smith KE, Stenzel SA, Bender JB, Wagstrom E, Soderlund D, Leano FT, et al. Outbreaks of enteric infections caused by multiple pathogens associated with calves at a farm day camp. *Pediatr Infect Dis J*. 2004;23:1098–104. [PubMed](#)
29. Ogunmodede F, Jones JL, Scheftel J, Kirkland E, Schulkin J. Listeriosis prevention knowledge among pregnant women in the USA. *Infect Dis Obstet Gynecol*. 2005;13:11–5. [PubMed](#)
<http://dx.doi.org/10.1155/2005/734814>
30. Johnson JR, Delavari P, O’Bryan TT, Smith KE, Tatini S. Contamination of retail foods, particularly turkey, from community markets (Minnesota, 1999–2000) with antimicrobial-resistant and extraintestinal pathogenic *Escherichia coli*. *Foodborne Pathog Dis*. 2005;2:38–49. [PubMed](#)
<http://dx.doi.org/10.1089/fpd.2005.2.38>
31. Johnson JR, Kuskowski MA, Smith K, O’Bryan TT, Tatini S. Antimicrobial-resistant and extraintestinal pathogenic *Escherichia coli* in retail foods. *J Infect Dis*. 2005;191:1040–9. [PubMed](#) <http://dx.doi.org/10.1086/428451>
32. Kiang KM, Kieke BA, Como-Sabetti K, Lynfield R, Besser RE, Belongia E. Clinician knowledge and beliefs after statewide program to promote appropriate antimicrobial drug use. *Emerg Infect Dis*. 2005;11:904–11. [PubMed](#) <http://dx.doi.org/10.3201/eid1106.050144>

33. Laine ES, Scheftel JM, Boxrud DJ, Vought KJ, Danila RN, Elfering KM, et al. Outbreak of *Escherichia coli* O157:H7 infections associated with nonintact blade-tenderized frozen steaks sold by door-to-door vendors. J Food Prot. 2005;68:1198–202. [PubMed](#)
34. Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. Emerg Infect Dis. 2005;11:977–9. [PubMed](#)
<http://dx.doi.org/10.3201/eid1106.050143>
35. Smith KE, Anderson F, Medus C, Leano F, Adams J. Outbreaks of salmonellosis at elementary schools associated with dissection of owl pellets. Vector Borne Zoonotic Dis. 2005;5:133–6. [PubMed](#) <http://dx.doi.org/10.1089/vbz.2005.5.133>
36. Morin CA, White K, Schuchat A, Danila R, Lynfield R. Perinatal group B streptococcal disease prevention, Minnesota. Emerg Infect Dis. 2005;11:1467–9. [PubMed](#)
<http://dx.doi.org/10.3201/eid1109.041109>
37. Buck JM, Como-Sabetti K, Harriman KH, Danila RN, Boxrud DJ, Glennen A, et al. Community-associated methicillin-resistant *Staphylococcus aureus* infections: Minnesota, 2000–2003. Emerg Infect Dis. 2005;11:1532–8. [PubMed](#) <http://dx.doi.org/10.3201/eid1110.050141>
38. Wedel SD, Bender JB, Leano FT, Boxrud D, Hedberg C, Smith KE. Antimicrobial susceptibility and pulsed-field gel electrophoresis profiles of clinical *Salmonella* Typhimurium isolates of human and animal origin in Minnesota, 1997–2003. Emerg Infect Dis. 2005;11:1899–906. [PubMed](#)
<http://dx.doi.org/10.3201/eid1112.050158>
39. Kiang KM, Scheftel JM, Leano FT, Taylor CM, Belle-Isle PA, Cebelinski EA, et al. Recurrent outbreaks of cryptosporidiosis associated with calves among students at an educational farm programme, Minnesota, 2003. Epidemiol Infect. 2006;134:878–86. [PubMed](#)
<http://dx.doi.org/10.1017/S0950268805005649>
40. Liesener AL, Smith KE, Davis RD, Bender JB, Danila RN, Neitzel DF, et al. Circumstances of bat encounters and knowledge of rabies among Minnesota residents submitting bats for rabies testing. Vector Borne Zoonotic Dis. 2006;6:208–15. [PubMed](#) <http://dx.doi.org/10.1089/vbz.2006.6.208>
41. Medus C, Smith KE, Bender JB, Besser JM, Hedberg CW. *Salmonella* outbreaks in restaurants in Minnesota, 1995 through 2003: evaluation of the role of infected foodworkers. J Food Prot. 2006;69:1870–8. [PubMed](#)

42. Buck JM, Lexau C, Shapiro M, Glennen A, Boxrud D, Koziol B, et al. Community outbreak of conjunctivitis caused by nontypeable *Streptococcus pneumoniae* in Minnesota. *Pediatr Infect Dis J*. 2006;25:906–11. [PubMed http://dx.doi.org/10.1097/01.inf.0000238143.96607.ec](http://dx.doi.org/10.1097/01.inf.0000238143.96607.ec)
43. Swanson SJ, Neitzel D, Reed KD, Belongia EA. Coinfections acquired from *Ixodes* ticks. *Clin Microbiol Rev*. 2006;19:708–27. [PubMed http://dx.doi.org/10.1128/CMR.00011-06](http://dx.doi.org/10.1128/CMR.00011-06)
44. Como-Sabeti K, Harriman K, Juni B, Westbrook A, Cebelinski E, Boxrud D, et al. Methicillin resistant *Staphylococcus aureus* at canoe camp. *Emerg Infect Dis*. 2006;12:1759–61. [PubMed http://dx.doi.org/10.3201/eid1211.060363](http://dx.doi.org/10.3201/eid1211.060363)
45. Swanson SJ, Snider C, Braden CR, Boxrud D, Wunschmann A, Rudroff JA, et al. Multidrug-resistant *Salmonella enterica* serotype Typhimurium associated with pet rodents. *N Engl J Med*. 2007;356:21–8. [PubMed http://dx.doi.org/10.1056/NEJMoa060465](http://dx.doi.org/10.1056/NEJMoa060465)
46. Boxrud D, Pederson-Gulrud K, Wotton J, Medus C, Lyszkowicz E, Besser J, et al. Comparison of multiple-locus variable-number tandem repeat analysis, pulsed-field gel electrophoresis, and phage typing for subtype analysis of *Salmonella enterica* serotype Enteritidis. *J Clin Microbiol*. 2007;45:536–43. [PubMed http://dx.doi.org/10.1128/JCM.01595-06](http://dx.doi.org/10.1128/JCM.01595-06)
47. Gahr P, Harper J, Kieke B Jr, Como-Sabeti K, Craig Christianson R, Williams D, et al. Healthcare professional surveys: judicious antibiotic use in Minnesota long-term care facilities. *J Am Geriatr Soc*. 2007;55:473–4. [PubMed http://dx.doi.org/10.1111/j.1532-5415.2007.01080.x](http://dx.doi.org/10.1111/j.1532-5415.2007.01080.x)
48. Jungk J, Como-Sabeti K, Stinchfield P, Ackerman P, Harriman K. Epidemiology of methicillin-resistant *Staphylococcus aureus* at a pediatric healthcare system, 1991–2003. *Pediatr Infect Dis J*. 2007;26:339–44. [PubMed http://dx.doi.org/10.1097/01.inf.0000257452.58182.e1](http://dx.doi.org/10.1097/01.inf.0000257452.58182.e1)
49. Johnson JR, Sannes MR, Croy C, Johnson B, Clabots C, Kuskowski MA, et al. Antimicrobial drug-resistant *Escherichia coli* from humans and poultry products, Minnesota and Wisconsin, 2002–2004. *Emerg Infect Dis*. 2007;13:838–46. [PubMed http://dx.doi.org/10.3201/eid1306.061576](http://dx.doi.org/10.3201/eid1306.061576)
50. O’Fallon E, Harper J, Shaw S, Lynfield R. Antibiotic and infection tracking in Minnesota long-term care facilities. *J Am Geriatr Soc*. 2007;55:1243–7. [PubMed http://dx.doi.org/10.1111/j.1532-5415.2007.01247.x](http://dx.doi.org/10.1111/j.1532-5415.2007.01247.x)
51. Triden L, Glennen A, Juni B, Lynfield R. Invasive *Haemophilus influenzae* disease and antibiotic susceptibility of invasive isolates in Minnesota, 2002–2005. *Infect Dis Clin Pract*. 2007;15:373–6. <http://dx.doi.org/10.1097/IPC.0b013e318157d260>

52. Sannes MR, Belongia EA, Kieke B, Smith K, Kieke A, Vandermause M, et al. Predictors of antimicrobial-resistant *Escherichia coli* in the feces of vegetarians and newly hospitalized adults in Minnesota and Wisconsin. *J Infect Dis*. 2008;197:430–4. [PubMed](#)
<http://dx.doi.org/10.1086/525530>
53. Centers for Disease Control and Prevention. Emergence of fluoroquinolone-resistant *Neisseria meningitidis*—Minnesota and North Dakota, 2007–2008 [Minnesota section]. *MMWR Morb Mortal Wkly Rep*. 2008;57:173–5. [PubMed](#)
54. Lexau CA. Changing epidemiology of pneumococcal pulmonary disease in the era of the heptavalent vaccine. *Curr Infect Dis Rep*. 2008;10:229–35. [PubMed](#) <http://dx.doi.org/10.1007/s11908-008-0038-3>
55. Buck JM, Harriman KH, Juni BA, Gall K, Boxrud DJ, Glennen A, et al. No change in methicillin-resistant *Staphylococcus aureus* nasal colonization rates among Minnesota school children during 2 study periods. *Infect Dis Clin Pract*. 2008;16:163–5.
<http://dx.doi.org/10.1097/IPC.0b013e318168ff48>
56. Rainbow J, Jewell B, Danila RN, Boxrud D, Beall B, Van Beneden C, et al. Invasive group A streptococcal disease in nursing homes, Minnesota, 1995–2006. *Emerg Infect Dis*. 2008;14:772–7. [PubMed](#)
57. Fuller CC, Jawahir SL, Leano FT, Bidol SA, Signs K, Davis C, et al. Multi-state *Salmonella* Typhimurium outbreak associated with frozen vacuum-packed rodents used to feed snakes. *Zoonoses Public Health*. 2008;55:481–7. [PubMed](#)
58. Smith KE, Medus C, Meyer SD, Boxrud DJ, Leano F, Hedberg CW, et al. Outbreaks of salmonellosis in Minnesota (1998 to 2006) associated with frozen, microwaveable, breaded, stuffed chicken products. *J Food Prot*. 2008;71:2153–60. [PubMed](#)
59. Como-Sabetti K, Harriman KH, Buck JM, Glennen A, Boxrud DJ, Lynfield R. Community-associated methicillin-resistant *Staphylococcus aureus*: trends in case and isolate characteristics from six years of prospective surveillance. *Public Health Rep*. 2009;124:427–35. [PubMed](#)
60. Leshner L, DeVries A, Danila R, Lynfield R. Evaluation of surveillance methods for staphylococcal toxic shock syndrome. *Emerg Infect Dis*. 2009;15:770–3. [PubMed](#)
<http://dx.doi.org/10.3201/eid1505.080826>

61. Hedican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, et al. Characteristics of O157 versus non-O157 Shiga toxin-producing *Escherichia coli* infections in Minnesota, 2000–2006. *Clin Infect Dis.* 2009;49:358–64. [PubMed http://dx.doi.org/10.1086/600302](http://dx.doi.org/10.1086/600302)
62. Kothari NJ, Morin CA, Glennen A, Jackson D, Harper J, Schrag SJ, et al. Invasive group B streptococcal disease in the elderly in Minnesota, USA, 2003–2007. *Emerg Infect Dis.* 2009;15:1279–81. [PubMed http://dx.doi.org/10.3201/eid1508.081381](http://dx.doi.org/10.3201/eid1508.081381)
63. Hedican E, Hooker C, Jenkins T, Medus C, Jawahir S, Leano F, et al. Restaurant *Salmonella* Enteritidis outbreak associated with an asymptomatic infected food worker. *J Food Prot.* 2009;72:2332–6. [PubMed](http://dx.doi.org/10.1188/09072332)
64. Holzbauer SM, DeVries AS, Sejvar JJ, Lees CH, Adjemian J, McQuiston JH, et al. Epidemiologic investigation of immune-mediated polyradiculoneuropathy among abattoir workers exposed to porcine brain. *PLoS ONE.* 2010;5:e9782. [PubMed http://dx.doi.org/10.1371/journal.pone.0009782](http://dx.doi.org/10.1371/journal.pone.0009782)
65. Robinson TJ, Cebelinski EA, Taylor C, Smith KE. Evaluation of the positive predictive value of rapid assays used by clinical laboratories in Minnesota for the diagnosis of cryptosporidiosis. *Clin Infect Dis.* 2010;50:e53–5. [PubMed http://dx.doi.org/10.1086/651423](http://dx.doi.org/10.1086/651423)
66. Boxrud D, Monson T, Stiles T, Besser J. The role, challenges, and support of PulseNet laboratories in detecting foodborne disease outbreaks. *Public Health Rep.* 2010;125(Suppl 2):57–62. [PubMed](http://dx.doi.org/10.1188/10025762)
67. Holzbauer SM, Kemperman MM, Lynfield R. Death due to community-associated *Clostridium difficile* in a woman receiving prolonged antibiotic therapy for suspected Lyme disease. *Clin Infect Dis.* 2010;51:369–70. [PubMed http://dx.doi.org/10.1086/654808](http://dx.doi.org/10.1086/654808)
68. Hedican E, Miller B, Ziemer B, Lemaster P, Jawahir S, Leano F, et al. Salmonellosis outbreak due to chicken contact leading to a foodborne outbreak associated with infected delicatessen workers. *Foodborne Pathog Dis.* 2010;7:995–7. [PubMed http://dx.doi.org/10.1089/fpd.2009.0495](http://dx.doi.org/10.1089/fpd.2009.0495)
69. Rounds JM, Hedberg CW, Meyer S, Boxrud D, Smith KE. *Salmonella nterica* pulsed-field gel electrophoresis clusters, Minnesota, USA, 2001–2007. *Emerg Infect Dis.* 2010;16:1678–85. [PubMed http://dx.doi.org/10.3201/eid1611.100368](http://dx.doi.org/10.3201/eid1611.100368)
70. Medus C, Smith KE, Bender JB, Leano F, Hedberg CW. *Salmonella* infections in food workers identified through public health surveillance in Minnesota: impact on outbreak recognition. *J Food Prot.* 2010;73:2053–8. [PubMed](http://dx.doi.org/10.1188/100732053)

71. Li J, Smith K, Kaehler D, Everstine K, Rounds J, Hedberg C. Evaluation of a statewide foodborne illness complaint surveillance system in Minnesota. *J Food Prot.* 2010;73:2059–64. [PubMed](#)
72. Scheftel JM, Griffith JM, Leppke BA, Pantlin GC, Snippes PM, Wunschmann A. Tularaemia in Minnesota: case report and brief epidemiology. *Zoonoses Public Health.* 2010;57:e165–9. [PubMed](#) <http://dx.doi.org/10.1111/j.1863-2378.2009.01318.x>
73. Li J, Maclehose R, Smith K, Kaehler D, Hedberg C. Development of a *Salmonella* screening tool for consumer complaint–based foodborne illness surveillance systems. *J Food Prot.* 2011;74:106–10. [PubMed](#) <http://dx.doi.org/10.4315/0362-028X.JFP-10-312>
74. Como-Sabeti KJ, Harriman KH, Fridkin SK, Jawahir SL, Lynfield R. Risk factors for community-associated *Staphylococcus aureus* infections: results from parallel studies including methicillin-resistant and methicillin-sensitive *S. aureus* compared to uninfected controls. *Epidemiol Infect.* 2011;139:419–29. [PubMed](#) <http://dx.doi.org/10.1017/S0950268810001111>
75. Lees CH, Avery C, Asherin R, Rainbow J, Danila R, Smelser C, et al. Pandemic (H1N1) 2009–associated deaths detected by unexplained death and medical examiner surveillance. *Emerg Infect Dis.* 2011;17:1479–83. [PubMed](#)
76. DeVries AS, Leshner L, Schlievert PM, Rogers T, Villaume LG, Danila R, et al. Staphylococcal toxic shock syndrome 2000–2006: epidemiology, clinical features, and molecular characteristics. *PLoS ONE.* 2011;6:e22997. [PubMed](#) <http://dx.doi.org/10.1371/journal.pone.0022997>
77. Nerby JM, Gorwitz R, Leshner L, Juni B, Jawahir S, Lynfield R, et al. Risk factors for household transmission of community-associated methicillin-resistant *Staphylococcus aureus*. *Pediatr Infect Dis J.* 2011;30:927–32. [PubMed](#) <http://dx.doi.org/10.1097/INF.0b013e31822256c3>
78. Lowther SA, Medus C, Scheftel J, Leano F, Jawahir S, Smith K. Foodborne outbreak of *Salmonella* subspecies IV infections associated with contamination from bearded dragons. *Zoonoses Public Health.* 2011;58:560–6. [PubMed](#) <http://dx.doi.org/10.1111/j.1863-2378.2011.01403.x>
79. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of *Escherichia coli* O157 infection and the risk of hemolytic uremic syndrome, Minnesota. *Pediatr Infect Dis J.* 2012;31:37–41. [PubMed](#) <http://dx.doi.org/10.1097/INF.0b013e31823096a8>
80. Rounds JM, Rigdon CE, Muhl LJ, Forstner M, Danzeisen GT, Koziol BS, et al. Non-O157 Shiga toxin–producing *Escherichia coli* infections associated with venison. *Emerg Infect Dis.* 2012;18:279–82. [PubMed](#) <http://dx.doi.org/10.3201/eid1802.110855>

81. Bender JB, Waters KC, Nerby J, Olsen KE, Jawahir S. Methicillin-resistant *Staphylococcus aureus* (MRSA) isolated from pets living in households with MRSA-infected children. Clin Infect Dis. 2012;54:449–50. [PubMed http://dx.doi.org/10.1093/cid/cir714](http://dx.doi.org/10.1093/cid/cir714)
82. Miller BD, Rigdon CE, Ball J, Rounds J, Klos R, Brennan BM, et al. Use of trace-back methods to confirm the source of a multi-state *E. coli* O157:H7 outbreak due to in-shell hazelnuts. J Food Prot. 2012;75:320–7. [PubMed http://dx.doi.org/10.4315/0362-028X.JFP-11-309](http://dx.doi.org/10.4315/0362-028X.JFP-11-309)
83. Lowther SA, Shinoda N, Juni BA, Theodore MJ, Wang X, Jawahir SL, et al. *Haemophilus influenzae* type b infection, vaccination, and *H. influenzae* carriage in children in Minnesota, 2008–2009. Epidemiol Infect. 2012;140:566–74. [PubMed http://dx.doi.org/10.1017/S0950268811000793](http://dx.doi.org/10.1017/S0950268811000793)
84. Koene R, Boulware DR, Kemperman M, Konety SH, Groth M, Jesserun J, et al. Acute heart failure from Lyme carditis. Circ Heart Fail. 2012;5:e24–6. [PubMed http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.965533](http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.965533)
85. Rounds JM, Boxrud DJ, Jawahir SL, Smith KE. Dynamics of *Escherichia coli* O157:H7 outbreak detection and investigation, Minnesota 2000–2008. Epidemiol Infect. 2012;140:1430–8. [PubMed http://dx.doi.org/10.1017/S0950268811002330](http://dx.doi.org/10.1017/S0950268811002330)
86. DeVries A, Wotton J, Lees C, Boxrud D, Uyeki T, Lynfield R. Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of pandemic influenza A (H1N1) virus infection. Influenza Other Respir Viruses. 2012;6:e85–8. [PubMed http://dx.doi.org/10.1111/j.1750-2659.2011.00329.x](http://dx.doi.org/10.1111/j.1750-2659.2011.00329.x)
87. Spaulding AB, Radi D, Macleod H, Lynfield R, Larson M, Hyduke T, et al. Design and implementation of a statewide influenza nurse triage line in response to pandemic H1N1 influenza. Public Health Rep. 2012;127:532–40. [PubMed http://dx.doi.org/10.1111/j.1750-2659.2011.00329.x](http://dx.doi.org/10.1111/j.1750-2659.2011.00329.x)
88. Spaulding AB, Radi D, Macleod H, Lynfield R, Larson M, Hyduke T, et al. Satisfaction and public health cost of a statewide influenza nurse triage line in response to pandemic H1N1 influenza. PLoS ONE. 2013;8:e50492. [PubMed http://dx.doi.org/10.1371/journal.pone.0050492](http://dx.doi.org/10.1371/journal.pone.0050492)
89. Fowler HN, Brown P, Rovira A, Shade P, Klammer K, Smith K, et al. *Streptococcus suis* meningitis in swine worker, Minnesota, USA. Emerg Infect Dis. 2013;19:330–1. [PubMed http://dx.doi.org/10.3201/eid1902.120918](http://dx.doi.org/10.3201/eid1902.120918)
90. Ferrieri P, Lynfield R, Creti R, Flores AE. Serotype IV and invasive group B *Streptococcus* disease in neonates, Minnesota, USA, 2000–2010. Emerg Infect Dis. 2013;19:551–8. [PubMed http://dx.doi.org/10.3201/eid1902.120918](http://dx.doi.org/10.3201/eid1902.120918)

91. Miller BD, Rigdon CE, Robinson TJ, Hedberg C, Smith KE. Use of global trade item numbers in the investigation of a *Salmonella* Newport outbreak associated with blueberries in Minnesota, 2010. J Food Prot. 2013;76:762–9. [PubMed](#) <http://dx.doi.org/10.4315/0362-028X.JFP-12-407>
92. Saupe AA, Kaehler D, Cebelinski EA, Nefzger B, Hall AJ, Smith KE. Norovirus surveillance among callers to foodborne illness complaint hotline, Minnesota, USA, 2011–2013. Emerg Infect Dis. 2013;19:1293–6. [PubMed](#) <http://dx.doi.org/10.3201/eid1908.130462>
93. Kemble SK, Westbrook A, Lynfield R, Bogard A, Kockavy N, Gall K, et al. Foodborne outbreak of group A *Streptococcus* pharyngitis associated with a high school dance team banquet—Minnesota, 2012. Clin Infect Dis. 2013;57:648–54. [PubMed](#) <http://dx.doi.org/10.1093/cid/cit359>
94. Bogard AK, Fuller CC, Radke V, Selman CA, Smith KE. Ground beef handling and cooking practices in restaurants in eight states. J Food Prot. 2013;76:2132–40. [PubMed](#) <http://dx.doi.org/10.4315/0362-028X.JFP-13-126>
95. Robinson TJ, Scheftel JM, Smith KE. Raw milk consumption among patients with non–outbreak-related enteric infections, Minnesota, USA, 2001–2010. Emerg Infect Dis. 2014;20:38–44. [PubMed](#)
96. Lynfield R, Schaffner W. Can we conquer coqueluche? J Infect Dis. 2014;209(Suppl 1):S1–3. [PubMed](#) <http://dx.doi.org/10.1093/infdis/jit487>
97. Kenyon C, Banerjee E, Sweet K, Miller C, Ehresmann K. Assessing the impact of a pertussis active surveillance program on provider testing behavior, Minnesota 2005–2009. Am J Public Health. 2014;104:e34–9. [PubMed](#) <http://dx.doi.org/10.2105/AJPH.2013.301815>
98. Pereira EC, Shaw KM, Vagnone PM, Harper JE, Kallen AJ, Limbago BM, et al. Thirty-day laboratory-based surveillance for carbapenem-resistant *Enterobacteriaceae* in the Minneapolis–St. Paul metropolitan area. Infect Control Hosp Epidemiol. 2014;35:423–5. [PubMed](#) <http://dx.doi.org/10.1086/675602>
99. Shaw KM, Harper JE, Vagnone PM, Lynfield R. Establishing surveillance for carbapenem-resistant *Enterobacteriaceae* in Minnesota, 2012. Infect Control Hosp Epidemiol. 2014;35:451–3. [PubMed](#) <http://dx.doi.org/10.1086/675615>
100. Whitten T, Bender JB, Smith K, Leano F, Scheftel J. Reptile-associated salmonellosis in Minnesota, 1996–2011. Zoonoses Public Health. 2015;62:199–208. [PubMed](#) <http://dx.doi.org/10.1111/zph.12140>

101. Klumb C, Saunders S, Smith K. *E. coli* O157:H7 surveillance in agricultural populations in Minnesota. *Journal of Agromedicine*. 2014;19:221.
<http://dx.doi.org/10.1080/1059924X.2014.890555>
102. Choi MJ, Morin CA, Scheftel J, Vetter SM, Smith K, Lynfield R, et al. Variant influenza associated with live animal markets, Minnesota. *Zoonoses Public Health*. 2014. Epub ahead of print.
[PubMed http://dx.doi.org/10.1111/zph.12139](http://dx.doi.org/10.1111/zph.12139)
103. Holzbauer SM, Agger WA, Hall RL, Johnson GM, Schmitt D, Garvey A, et al. Outbreak of *Trichinella spiralis* infections associated with consumption of wild boar hunted at a game farm in Iowa. *Clin Infect Dis*. 2014;59:1750–6. [PubMed http://dx.doi.org/10.1093/cid/ciu713](http://dx.doi.org/10.1093/cid/ciu713)
104. Robinson SJ, Neitzel DF, Moen RA, Craft ME, Hamilton KE, Johnson LB, et al. Disease risk in a dynamic environment: the spread of tick-borne pathogens in Minnesota, USA. *EcoHealth*. 2015;12:152–63. [PubMed http://dx.doi.org/10.1007/s10393-014-0979-y](http://dx.doi.org/10.1007/s10393-014-0979-y)
105. Danila RN, Eikmeier D, Robinson T, La Pointe A, DeVries A. Two concurrent enteric disease outbreaks among men who have sex with men, Minneapolis–St. Paul area. *Clin Infect Dis*. 2014;59:987–9. [PubMed http://dx.doi.org/10.1093/cid/ciu478](http://dx.doi.org/10.1093/cid/ciu478)
106. Fowler H, Scheftel J. Survey of occupational hazards in veterinary medicine, Minnesota 2012. *J Am Vet Med Assoc*. In press.

Published Multisite Analyses Led by Staff in EIP sites, Connecticut and Minnesota, 1995–2015

Connecticut

1. Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. *Pediatrics*. 2001;108:1094–8. [PubMed http://dx.doi.org/10.1542/peds.108.5.1094](http://dx.doi.org/10.1542/peds.108.5.1094)
2. Vanden Eng J, Marcus R, Hadler JL, Imhoff B, Vugia DJ, Cieslak P, et al. Consumer attitudes and use of antibiotics. *Emerg Infect Dis*. 2003;9:1128–35. [PubMed http://dx.doi.org/10.3201/eid0909.020591](http://dx.doi.org/10.3201/eid0909.020591)
3. Marcus R, Fiorentino T, Mohle-Boetani J, Farley MM, Medus C, Shiferaw B, et al. Dramatic decrease in *Salmonella* serotype Enteritidis (SE) in 5 FoodNet sites. 1996–1999. *Clin Infect Dis*. 2004;38(Suppl 3):S135–41. [PubMed http://dx.doi.org/10.1086/381579](http://dx.doi.org/10.1086/381579)

4. Heffernan RT, Barrett NL, Gallagher K, Hadler J, Harrison L, Reingold A, et al. Declining invasive *Streptococcus pneumoniae* infections among people living with AIDS in the era of highly-active antiretroviral therapy (HAART), 1995–2000. *J Infect Dis.* 2005;191:2038–45. [PubMed](#)
<http://dx.doi.org/10.1086/430356>
5. Sofair AN, Lyon GM, Huie-White S, Reiss E, Harrison LH, Sanza LT, et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. *Clin Infect Dis.* 2006;43:32–9. [PubMed](#) <http://dx.doi.org/10.1086/504807>
6. Marcus R, Varma JK, Medus C, Boothe EJ, Anderson BJ, Crume T, et al. Re-assessment of risk factors for sporadic *Salmonella* serotype Enteritidis infections: a case–control study in five FoodNet sites. 2002–2003. *Epidemiol Infect.* 2007;135:84–92. [PubMed](#)
<http://dx.doi.org/10.1017/S0950268806006558>
7. Ferrucci LM, Bell BP, Dhotre KB, Manos MM, Terrault NA, Zaman A, et al. Complementary and alternative medicine use in chronic liver disease patients. *J Clin Gastroenterol.* 2010;44:e40–5. [PubMed](#) <http://dx.doi.org/10.1097/MCG.0b013e3181b766ed>
8. Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, et al. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. *J Clin Gastroenterol.* 2010;44:301–7. [PubMed](#)
<http://dx.doi.org/10.1097/MCG.0b013e3181b3f760>
9. Hurd S, Patrick M, Hatch J, Clogher P, Wymore K, Cronquist AB, et al. Clinical laboratory practices for the isolation and identification of *Campylobacter* in Foodborne Diseases Active Surveillance Network (FoodNet) sites: baseline information for understanding changes in surveillance data. *Clin Infect Dis.* 2012;54(Suppl 5):S440–5. [PubMed](#) <http://dx.doi.org/10.1093/cid/cis245>
10. Clogher P, Hurd S, Hoefler D, Hadler J, Pasutti L, Cosgrove S, et al. Assessment of physician knowledge and practices concerning STEC infection and enteric illness, 2009, FoodNet. *Clin Infect Dis.* 2012;54(suppl 5):S446–52. [PubMed](#) <http://dx.doi.org/10.1093/cid/cis246>

Minnesota

1. Kassenborg HD, Hedberg CW, Hoekstra M, Evans MC, Chin AE, Marcus R, et al. Farm visits and undercooked hamburgers as major risk factors for sporadic *Escherichia coli* O157:H7 infection: data from a case–control study in 5 FoodNet sites. *Clin Infect Dis.* 2004;38(Suppl 3):S271–8. [PubMed](#) <http://dx.doi.org/10.1086/381596>

2. Kassenborg HD, Smith KE, Vugia DJ, Rabatsky-Ehr T, Bates MR, Carter MA, et al. Fluoroquinolone-resistant *Campylobacter* infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis. 2004;38(Suppl 3):S279–84. [PubMed http://dx.doi.org/10.1086/381597](http://dx.doi.org/10.1086/381597)
3. Bender JB, Smith KE, McNees AA, Rabatsky-Ehr TR, Segler SD, Hawkins MA, et al. Factors affecting surveillance data on *Escherichia coli* O157 infections collected from FoodNet sites, 1996–1999. Clin Infect Dis. 2004;38(Suppl 3):S157–64. [PubMed http://dx.doi.org/10.1086/381582](http://dx.doi.org/10.1086/381582)
4. Nelson JM, Smith KE, Vugia DJ, Rabatsky-Ehr T, Segler SD, Kassenborg HD, et al. Prolonged diarrhea due to ciprofloxacin-resistant *Campylobacter* infection. J Infect Dis. 2004;190:1150–7. [PubMed http://dx.doi.org/10.1086/423282](http://dx.doi.org/10.1086/423282)
5. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–51. [PubMed http://dx.doi.org/10.1001/jama.294.16.2043](http://dx.doi.org/10.1001/jama.294.16.2043)
6. Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol. 2008;2008:727505.